3,391 trials (keyword fallback)
Leukemia · Myelodysplastic Syndromes
Primary: Number of Patients Experiencing Regimen-related Toxicity Events in Study Population — 2; 5 participants
Leukemia
Primary: Complete Remission (CR) Rate (Including CR With Incomplete Recovery) — 27; 14; 14 Participants
Thyroid Cancer · Anaplastic Thyroid Cancer · Undifferentiated Thyroid Cancer
Primary: Number of Participants With Overall Response (OR) — 0 Participants
Sarcoma
Primary: Number of Patients With Dose Limiting Toxicities. — 0; 1; 0 Participants
Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Time to Failure — 16; 13 Days
Acute Biphenotypic Leukemia · Acute Lymphoblastic Leukemia in Remission · Acute Myeloid Leukemia in Remission
Primary: Time to Neutrophil Engraftment — 20.0; 22.0 days
Acute Myeloid Leukemia (AML) · Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Primary: Overall Survival (OS) — 9.82; 9.23; 5.24 months — p=0.523
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Acute Biphenotypic Leukemia · Acute Leukemia of Ambiguous Lineage
Primary: Chronic GVHD — 17; 20; 14; 17 Participants
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Adult Acute Myeloid Leukemia in Remission · Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
Primary: Proportion of Patients With Clinical Response — 0.32; 0.27; 0.46; 0.17 Proportion of patients
Adult Acute Myeloid Leukemia · Secondary Acute Myeloid Leukemia · Therapy-Related Acute Myeloid Leukemia
Primary: Rate of Complete Remission and Mortality in the Entire Cohort of Older Patients — 21.9; 52.0 percentage of subjects
Acute Myeloid Leukemia Post Cytotoxic Therapy · Recurrent Childhood Acute Myeloid Leukemia · Secondary Acute Myeloid Leukemia
Primary: Number of Participants With a Dose-limiting Toxicity — 1 Participants
Drug/Agent Toxicity by Tissue/Organ · Leukemia
Primary: Asparaginase-Related Toxicity Rate — 26; 28 percentage of participants — p=.60
Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Primary: Response (Complete and Partial Response) in Patients With Myeloid Disorders — 0; 1; 2; 5 Participants
Leukemia
Primary: Measure Patient Response to High-dose Cytarabine Followed by Clofarabine in Adult Patients With Relapsed or Refractory AML — 17 participants
Accelerated Phase Chronic Myelogenous Leukemia · Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Myeloid Leukemia in Remission
Primary: Relapse Incidence — 18 Participants